Document Detail

Early Activation of the Kynurenine Pathway Predicts Early Death and Long-term Outcome in Patients Resuscitated From Out-of-Hospital Cardiac Arrest.
MedLine Citation:
PMID:  25092787     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: The kynurenine pathway (KP) is the major route of tryptophan (TRP) catabolism and is activated by inflammation and after cardiac arrest in animals. We hypothesized that the KP activation level correlates with severity of post-cardiac arrest shock, early death, and long-term outcome.
METHODS AND RESULTS: Plasma was obtained from 245 patients enrolled in a prospective multicenter observational study in 21 intensive care units in Finland. Time to return of spontaneous circulation, lowest systolic arterial pressure, and bicarbonate during the first 24 hours were collected. A cerebral performance category of 3 to 5 defined 12-month poor outcome. Plasma TRP and KP metabolites, kynurenine (KYN), kynurenic acid, 3-hydroxyanthranilic acid, and the ratio of KYN to TRP were measured by liquid chromatography and mass spectrometry. All KP metabolites at intensive care unit admission were significantly higher in cardiac arrest patients with a nonshockable rhythm compared to those with a shockable rhythm, and kynurenic acid and 3-hydroxyanthranilic acid correlated with time to return of spontaneous circulation. Patients with higher levels of KYN, KYN to TRP, kynurenic acid, and 3-hydroxyanthranilic acid had lower 24-hour systolic arterial pressure and bicarbonate. All KP metabolites and the ratio of KYN to TRP, but not TRP, were significantly higher in patients who died in the intensive care unit in comparison to those who survived. Multivariable logistic regression showed that high kynurenic acid (odds ratio: 1.004; 95% confidence interval: 1.001 to 1.008; P=0.014), and 3-hydroxyanthranilic acid (odds ratio: 1.011; 95% confidence interval: 1.001 to 1.022; P=0.03) were independently associated with 12-month poor outcome and significantly improved risk reclassification.
CONCLUSIONS: KP is activated early after cardiac arrest and is associated with severity of post-cardiac arrest shock, early death, and poor long-term outcome.
Giuseppe Ristagno; Roberto Latini; Jukka Vaahersalo; Serge Masson; Jouni Kurola; Tero Varpula; Jacopo Lucchetti; Claudia Fracasso; Giovanna Guiso; Alessandro Montanelli; Simona Barlera; Marco Gobbi; Marjaana Tiainen; Ville Pettilä; Markus B Skrifvars;
Related Documents :
6718477 - Biotransformation of hexapropymate in man. part 2: isolation and identification of meta...
22347577 - The influence of riboflavin and nicotinic acid on shigella sonnei colony conversion.
6662867 - The analysis of [14c]clofibric acid glucuronide and [14c]clofibric acid in plasma and u...
18267137 - Extraction of domoic acid from seawater and urine using a resin based on 2-(trifluorome...
1236737 - Changes in plasma amino acid concentrations in man after ingestion of an amino acid mix...
23883077 - Cytotoxic and potential anticancer constituents from the stems of schisandra pubescens.
Publication Detail:
Type:  Journal Article     Date:  2014-08-04
Journal Detail:
Title:  Journal of the American Heart Association     Volume:  3     ISSN:  2047-9980     ISO Abbreviation:  J Am Heart Assoc     Publication Date:  2014  
Date Detail:
Created Date:  2014-08-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101580524     Medline TA:  J Am Heart Assoc     Country:  England    
Other Details:
Languages:  eng     Pagination:  -     Citation Subset:  IM    
Copyright Information:
© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tumor necrosis factor-like weak inducer of apoptosis or fn14 deficiency reduce elastase perfusion-in...
Next Document:  Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopa...